Skip to content

Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?

Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02666560
Enrollment
19
Registered
2016-01-28
Start date
2015-04-30
Completion date
2015-05-31
Last updated
2016-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Children

Keywords

Auditory Cueing, Gait

Brief summary

To determine the clinical efficacy of auditory cueing using a cross over design to investigate whether increasing auditory cueing frequency by 20% above self paced cadence affects gait parameters in children with Cerebral Palsy when performing a functional task.

Detailed description

Introduction: Cerebral Palsy is a non progressive disorder occurring in early brain development, resulting in inefficient ambulatory pattern. The use of sensory cues to facilitate loco-motor activity has been suggested as providing the necessary trigger to synchronise movement with greater beneficial outcomes observed at higher frequency intensities within the adult population. Thus auditory cueing could have the potential to alter gait parameters during a functional task. Aim: To explore if increasing auditory cueing frequency (AC20) affects gait during a functional task compared to auditory cueing at self-paced cadence (ACSC). Method: Nineteen children with CP levels 1 and 2 on the Gross Motor Function Classification Scale participated using paired analysis. Outcomes were compared to the mean values for temporal spatial gait data within the conditions using a cross over design. TS data was obtained by using the GAITRite® walkway system whilst walking holding a cup.

Interventions

Auditory cueing set at different frequency rates

Sponsors

Gateshead Health NHS Foundation Trust
CollaboratorOTHER
Institute of Child Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
5 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* Children with Cerebral Palsy aged 5 to 11 years old who were scored as levels 1 to 2 on the Gross Motor Function Classification Scale. * Cognitive status average or above on the Weschler Intelligence Scale for children. * Able to hear without the use of a hearing aid.

Exclusion criteria

* Hearing impairment that results in the use of a hearing aid. * Walking with assistance of a mobility aid. * Cardiovascular problems or other associated health problems which limits the child waking multiple times over the GAITRite®.

Design outcomes

Primary

MeasureTime frameDescription
Step Length as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of length was recorded in centimetres.

Secondary

MeasureTime frameDescription
Velocity as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of velocity was recorded in cm's per second.
Step Time as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of step time was recorded in seconds.
Cadence as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of cadence was recorded in steps per minute.
Time Spent in Double Support as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. This was record in percentage of time spent in double support (%).
Time Spent in Single Support as Measured by the Gaitrite Walk-way System.Data was collected at a single time point for each condition. Conditions occurred within a two week time period.The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. This was record in percentage of time spent in double support (%).

Participant flow

Recruitment details

Recruitment occurred at an NHS FoundationTrust between March to April 2015. Twenty-six children with Cerebral Palsy who were currently on the paediatric physiotherapy caseload met the inclusion criteria, so were invited to participate. A total of nineteen children chose to participate in this research project.

Participants by arm

ArmCount
All Study Participants
Participants performed a functional task with auditory cueing set at self paced cadence and 20% above self paced cadence. Auditory Cueing: This was delivered by a metronome producing a beat which was set at the participant's baseline cadence or 20% above baseline cadence. This was a crossover design where participants completed both arms in the trial.
19
Total19

Baseline characteristics

CharacteristicAll Study Participants
Age, Categorical
<=18 years
19 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous104.3 months
STANDARD_DEVIATION 25.5
Sex: Female, Male
Female
11 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 190 / 19
serious
Total, serious adverse events
0 / 190 / 19

Outcome results

Primary

Step Length as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of length was recorded in centimetres.

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCStep Length as Measured by the Gaitrite Walk-way System.51.32 cmStandard Deviation 6.42
AC20Step Length as Measured by the Gaitrite Walk-way System.53.36 cmStandard Deviation 8.07
Secondary

Cadence as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of cadence was recorded in steps per minute.

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCCadence as Measured by the Gaitrite Walk-way System.115.27 steps per minuteStandard Deviation 15.75
AC20Cadence as Measured by the Gaitrite Walk-way System.117.09 steps per minuteStandard Deviation 15.97
Secondary

Step Time as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of step time was recorded in seconds.

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCStep Time as Measured by the Gaitrite Walk-way System.0.53 secondsStandard Deviation 0.09
AC20Step Time as Measured by the Gaitrite Walk-way System.0.52 secondsStandard Deviation 0.08
Secondary

Time Spent in Double Support as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. This was record in percentage of time spent in double support (%).

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCTime Spent in Double Support as Measured by the Gaitrite Walk-way System.0.30 percentage of timeStandard Deviation 0.91
AC20Time Spent in Double Support as Measured by the Gaitrite Walk-way System.0.29 percentage of timeStandard Deviation 0.09
Secondary

Time Spent in Single Support as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. This was record in percentage of time spent in double support (%).

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCTime Spent in Single Support as Measured by the Gaitrite Walk-way System.0.38 percentage of timeStandard Deviation 0.05
AC20Time Spent in Single Support as Measured by the Gaitrite Walk-way System.0.39 percentage of timeStandard Deviation 0.05
Secondary

Velocity as Measured by the Gaitrite Walk-way System.

The Gaitrite is a portable gait analysis walk-way system that enables the temprospatial measures of gait to be recorded. The temprospatial measure of velocity was recorded in cm's per second.

Time frame: Data was collected at a single time point for each condition. Conditions occurred within a two week time period.

ArmMeasureValue (MEAN)Dispersion
ACSCVelocity as Measured by the Gaitrite Walk-way System.98.62 cm/sStandard Deviation 16.29
AC20Velocity as Measured by the Gaitrite Walk-way System.101.77 cm/sStandard Deviation 21.08

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026